Related references
Note: Only part of the references are listed.Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo
Huanjie Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IκB kinase
Ivana von Metzler et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
J. H. Mendler et al.
ANNALS OF ONCOLOGY (2008)
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
P. Schmid et al.
ANNALS OF ONCOLOGY (2008)
Many facets of bortezomib resistance/susceptibility
Shaji Kumar et al.
BLOOD (2008)
Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy
John M. Pendleton et al.
BMC CANCER (2008)
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
A. Awada et al.
BRITISH JOURNAL OF CANCER (2008)
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
Sundar Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Multi-targeted therapy of cancer by genistein
Sanjeev Banerjee et al.
CANCER LETTERS (2008)
Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins
Ajaikumar B. Kunnumakkara et al.
CANCER LETTERS (2008)
Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo
Vesna Milacic et al.
CANCER RESEARCH (2008)
Bortezomib-Mediated Inhibition of Steroid Receptor Coactivator-3 Degradation Leads to Activated Akt
Gustavo Ayala et al.
CLINICAL CANCER RESEARCH (2008)
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells
Callum M. Sloss et al.
CLINICAL CANCER RESEARCH (2008)
Phase II trial of curcumin in patients with advanced pancreatic cancer
Navneet Dhillon et al.
CLINICAL CANCER RESEARCH (2008)
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours
S. Cresta et al.
EUROPEAN JOURNAL OF CANCER (2008)
The potential of proteasome inhibitors in cancer therapy
Jan Sterz et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer
Pedro T. Ramirez et al.
GYNECOLOGIC ONCOLOGY (2008)
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
Donna E. Reece et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway
Prashanthi Javvadi et al.
MOLECULAR PHARMACOLOGY (2008)
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
M. Pineda-Roman et al.
LEUKEMIA (2008)
Effects of a high daily dose of soy isoflavones on DNA damage, apoptosis, and estrogenic outcomes in healthy postmenopausal women: a phase I clinical trial
Elena A. Pop et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Concurrent radiation therapy and bortezomib in myeloma patient
Oscar Berges et al.
RADIOTHERAPY AND ONCOLOGY (2008)
Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis
I. A. Siddiqui et al.
ONCOGENE (2008)
Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment
Joan Blade et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population
R. Venkitaraman et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2008)
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
Michael J. Morris et al.
JOURNAL OF UROLOGY (2007)
Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China
Johanna W. Lampe et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience
Ryan H. Engel et al.
CANCER INVESTIGATION (2007)
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
Angela M. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial
Paul G. Richardson et al.
BLOOD (2007)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent
Kristin R. Landis-Piwowar et al.
CANCER RESEARCH (2007)
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions
Kenneth C. Anderson
EXPERIMENTAL HEMATOLOGY (2007)
Radiosensitization dependent on p53 function in bronchial carcinoma cells by the isoflavone genistein and estradiol in vitro
Robert Michael Hermann et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2007)
被撤回的出版物: Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo (Retracted article. See vol. 78, pg. 6028, 2018)
Julian J. Raffoul et al.
CANCER RESEARCH (2007)
Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway
Mao Li et al.
CANCER RESEARCH (2007)
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma
Christian Jakob et al.
BLOOD (2007)
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: A minnie pearl cancer research network phase II trial
John D. Hainsworth et al.
CLINICAL GENITOURINARY CANCER (2007)
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer
Robert Dreicer et al.
CLINICAL CANCER RESEARCH (2007)
The tumor proteasome is a primary target for the natural anticancer compound withaferin a isolated from Indian Winter Cherry
Huanjie Yang et al.
MOLECULAR PHARMACOLOGY (2007)
A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150
A. Belch et al.
ANNALS OF ONCOLOGY (2007)
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells
M. Kraus et al.
LEUKEMIA (2007)
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
E. Terpos et al.
LEUKEMIA (2007)
Lycopene and soy isoflavones in the treatment of prostate cancer
Ulka Vaishampayan et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2007)
A phase II randomized, placebo-controlled clinical trial of purified Isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer
Nagi B. Kumar et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2007)
A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
David R. Ryan et al.
CANCER (2006)
Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity
Di Chen et al.
CANCER RESEARCH (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Ulrike Heider et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies
TD Shanafelt et al.
LEUKEMIA RESEARCH (2006)
Bortezomib (VELCADE®) in metastatic breast cancer:: pharmacodynamics, biological effects, and prediction of clinical benefits
CH Yang et al.
ANNALS OF ONCOLOGY (2006)
Celastrol, a triterpene extracted from the Chinese Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice
Huanjie Yang et al.
CANCER RESEARCH (2006)
Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility
MM Chan et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
The role of Genistein and synthetic derivatives of isoflavone in cancer prevention and therapy
FH Sarkar et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2006)
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma
A Younes et al.
BLOOD (2006)
Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study
S Bettuzzi et al.
CANCER RESEARCH (2006)
Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients
S Ciolli et al.
LEUKEMIA & LYMPHOMA (2006)
Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development
S Tsukamoto et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma
C Van Waes et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA:: Effectiveness of a dietary supplement
FH Schröder et al.
EUROPEAN UROLOGY (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study
SR Alberts et al.
ANNALS OF ONCOLOGY (2005)
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer
C Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
SE Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis
A Goel et al.
EXPERIMENTAL HEMATOLOGY (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
HE Oakervee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: Case report
MM Mohiuddin et al.
JOURNAL OF CHEMOTHERAPY (2005)
Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells
D Chen et al.
BIOCHEMICAL PHARMACOLOGY (2005)
A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach
E Choan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Curcumin: A new radio-sensitizer of squamous cell carcinoma cells
A Khafif et al.
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I study of green tea extract in patients with advanced lung cancer
SA Laurie et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration
G Garcea et al.
BRITISH JOURNAL OF CANCER (2004)
Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3
D Chendil et al.
ONCOGENE (2004)
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
MH Shah et al.
CLINICAL CANCER RESEARCH (2004)
Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells
DZ Cen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Protective effect of green tea against prostate cancer: A case-control study in southeast China
L Jian et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
CN Papandreou et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance
RA Sharma et al.
CLINICAL CANCER RESEARCH (2004)
Proteasome-mediated destruction of the cyclin A/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo
W Chen et al.
CANCER RESEARCH (2004)
Clinical characteristics and pharmacokinetics of purified soy isoflavones: Multiple-dose administration to men with prostate neoplasia
L Fischer et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2004)
Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein
A Kazi et al.
BIOCHEMICAL PHARMACOLOGY (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer
W Miltyk et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2003)
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma
A Jatoi et al.
CANCER (2003)
Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora
RH Feling et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2003)
Mechanisms of cancer chemoprevention by soy isoflavone genistein
FH Sarkar et al.
CANCER AND METASTASIS REVIEWS (2002)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Radiosensitization by overexpression of the nonphosphorylation form of IκB-α in human glioma cells
N Honda et al.
JOURNAL OF RADIATION RESEARCH (2002)
Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men
MG Busby et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2002)
Cu/Zn superoxide dismutase plays a role in angiogenesis
M Marikovsky et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo
S Nam et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression
BY Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay
M Uehara et al.
BIOFACTORS (2000)
Share Paper
